ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be two presentations regarding trastuzumab-DM1 (T-DM1) at the 2009 Annual Meeting of the American Society of Clinical Oncology (ASCO) at the Orange County Convention Center in Orlando, Florida. T-DM1 consists of ImmunoGen’s DM1 cancer-cell killing agent linked to the HER2-targeted antibody, trastuzumab, developed by Genentech (a wholly-owned member of the Roche Group). A broad T-DM1 clinical program is being conducted by Genentech (US) and Roche (ex-US). Details regarding the titles, times and locations of these presentations are provided below.

MORE ON THIS TOPIC